Can exercise ease chemo nerve damage? new trial tests shorter programme
NCT ID NCT07307690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares an 8-week versus a 12-week supervised exercise programme in 50 colorectal cancer patients receiving chemotherapy. The goal is to see if exercise can reduce chemotherapy-induced peripheral neuropathy—nerve damage causing tingling, numbness, and pain—and improve quality of life. Participants will do two 50-minute sessions per week with a physiotherapist, including strength and flexibility exercises.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- supervised physical exercise programme
- What this could lead to
- If it works, this could show that a shorter 8-week exercise programme is as effective as a 12-week one for reducing nerve pain and improving daily life.
- What could go wrong
- This is a small, early-stage trial with only 50 participants, so results may not apply to all patients. Exercise might not reduce nerve symptoms for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * People diagnosed with colorectal cancer and who are receiving chemotherapy treatment. * Sedentary people who have not performed physical activity in the last 8 weeks. * Ability to understand the evaluation tests and the performance of the exercises. * Presence of XXX symptoms (If we focus on neuropathy, it should be inclusion criteria). * Voluntary participation in the study. Exclusion Criteria: \- Present contraindication/s for physical exercise (musculoskeletal diseases, severe cardiovascular disease, bone metastases,...).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lab test tell which chemo works for colon cancer?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days